Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach

We aimed to develop nafamostat mesylate immediate-release tablets for the treatment of COVID-19 through drug repositioning studies of nafamostat mesylate injection. Nafamostat mesylate is a serine protease inhibitor known to inhibit the activity of the transmembrane protease, serine 2 enzyme that af...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyeon-A, Kim, Joo-Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228348/
https://www.ncbi.nlm.nih.gov/pubmed/35745792
http://dx.doi.org/10.3390/pharmaceutics14061219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228348/
https://www.ncbi.nlm.nih.gov/pubmed/35745792
http://dx.doi.org/10.3390/pharmaceutics14061219

Ejemplares similares